CytomX Therapeutics (CTMX) Net Equity Issued and Repurchased (2014 - 2026)

CytomX Therapeutics' Net Equity Issued and Repurchased history runs 7 years deep, the most recent figure standing at $228.4 million for Q1 2026.

• Quarterly Net Equity Issued and Repurchased changed N/A year-over-year to $228.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $338.0 million (up 15927.69% YoY) and the FY2025 annual result came in at $109.6 million, up 1486.84% from the prior year.
• Net Equity Issued and Repurchased was $228.4 million for Q1 2026 at CytomX Therapeutics, up from $16.3 million in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $228.4 million in Q1 2026 and bottomed at $43000.0 in Q2 2024.
• A 3-year average of $68.0 million and a median of $16.3 million in 2025 frame the typical range for Net Equity Issued and Repurchased.
• Peak annual rise in Net Equity Issued and Repurchased reached 217046.51% in 2025, while the deepest fall reached 688.96% in 2025.
• CytomX Therapeutics' Net Equity Issued and Repurchased stood at $2.1 million in 2024, then jumped by 688.96% to $16.3 million in 2025, then surged by 1300.93% to $228.4 million in 2026.
• Business Quant data shows CTMX's Net Equity Issued and Repurchased at $228.4 million in Q1 2026, $16.3 million in Q4 2025, and $93.4 million in Q2 2025.